(secondQuint)A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants.

 There will be two arms.

 1200 healthy infants aged 2 months will be randomly assigned (1:1) to receive an experimental vaccine or a comparator vaccine in Month 0,2 and 4 (primary vaccination).

 All of them will receive a fourth dose as booster vaccination in Month 10.

.

 A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants@highlight

In order to evaluate immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine produced by Beijing Minhai Biotechnology Co.

, Ltd.

, a randomized, double-blind, parallel-controlled phase III clinical trial is planned to conduct in healthy infants aged 2 months in China.

